{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:10:56Z","timestamp":1790226656767,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.drudis.2024.104031","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T22:13:04Z","timestamp":1716502384000},"page":"104031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned"],"prefix":"10.1016","volume":"29","author":[{"given":"Milou A.","family":"Hogervorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"van Hattem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim G.","family":"Goettsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourens T.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104031_b0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/d41573-020-00015-1","article-title":"Tumour-agnostic therapies","volume":"19","author":"Looney","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104031_b0010","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S1470-2045(15)00620-8","article-title":"Precision oncology: origins, optimism, and potential","volume":"17","author":"Prasad","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0015","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00432-022-04412-4","article-title":"Pembrolizumab for all","volume":"149","author":"Kim","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0020","series-title":"European Public Assessment Report Rozlytrek","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2020"},{"key":"10.1016\/j.drudis.2024.104031_b0025","series-title":"European Public Assessment Report Vitrakvi","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2019"},{"key":"10.1016\/j.drudis.2024.104031_b0030","series-title":"International Classification of Diseases (ICD)","author":"WHO","year":"2022"},{"key":"10.1016\/j.drudis.2024.104031_b0035","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.3390\/ijms25074094","article-title":"Agnostic administration of targeted anticancer drugs: looking for a balance between hype and caution","volume":"25","author":"Aleksakhina","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104031_b0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104031_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100113","article-title":"Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours","volume":"6","author":"Paz-Ares","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.drudis.2024.104031_b0050","series-title":"Single-Arm Trials as Pivotal Evidence for the Authorisation of Medicines in EU","author":"European Medicines Agency","year":"2023"},{"key":"10.1016\/j.drudis.2024.104031_b0055","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jval.2021.11.1356","article-title":"Reported challenges in health technology assessment of complex health technologies","volume":"25","author":"Hogervorst","year":"2022","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.drudis.2024.104031_b0060","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S2468-2667(22)00057-3","article-title":"The ecosystem of health decision making: from fragmentation to synergy","volume":"7","author":"Sch\u00fcnemann","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.drudis.2024.104031_b0065","doi-asserted-by":"crossref","first-page":"e072309","DOI":"10.1136\/bmjopen-2023-072309","article-title":"Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts","volume":"13","author":"Hogervorst","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2024.104031_b0070","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/cts.13027","article-title":"Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies","volume":"14","author":"Bloem","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2024.104031_b0075","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/cpt.1251","article-title":"Weighing of evidence by health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally approved drugs","volume":"105","author":"Vreman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104031_b0080","first-page":"642","article-title":"The role of regulator-imposed post-approval studies in health technology assessments for conditionally approved drugs","volume":"11","author":"Vreman","year":"2022","journal-title":"Int J Health Policy Manag"},{"key":"10.1016\/j.drudis.2024.104031_b0085","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1017\/S0266462323000375","article-title":"Uncertainty management in regulatory and health technology assessment decision-making: guidance of the HTAi-DIA Working Group","volume":"39","author":"Hogervorst","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.drudis.2024.104031_b0090","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41571-020-0384-0","article-title":"Histology-agnostic drug development - considering issues beyond the tissue","volume":"17","author":"Pestana","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2024.104031_b0105","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/home. [Accessed May 12, 20224]."},{"key":"10.1016\/j.drudis.2024.104031_b0110","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0115","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2024.104031_b0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0125","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.31701","article-title":"The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas","volume":"124","author":"DuBois","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2024.104031_b0130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0140","first-page":"981","article-title":"The potential long-term comparative effectiveness of larotrectinib and entrectinib for second-line treatment of TRK fusion-positive metastatic lung cancer","volume":"26","author":"Roth","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.drudis.2024.104031_b0145","series-title":"Orphan Designation: Overview","author":"European Medicines Agency","year":"2024"},{"key":"10.1016\/j.drudis.2024.104031_b0150","series-title":"EU\/3\/15\/1580 - Orphan Designation for Treatment of Neuroblastoma","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.drudis.2024.104031_b0155","series-title":"Orphan Designation Withdrawal Assessment Report Vitrakvi (larotrectinib)","author":"Committee for Orphan Medicinal Products (COMP)","year":"2019"},{"key":"10.1016\/j.drudis.2024.104031_b0160","series-title":"Conditional Marketing Authorisation Medicinal Products Human Use Falling within the Scope of Regulation (EC) No 726\/2004)","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2016"},{"key":"10.1016\/j.drudis.2024.104031_b0165","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Vitrakvi. www.has-sante.fr\/jcms\/p_3193768\/en\/vitrakvi [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0170","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Rozlytrek (entrectinib) (tumeurs solides). www.has-sante.fr\/jcms\/p_3282231\/en\/rozlytrek-entrectinib-tumeurs-solides [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0175","unstructured":"IQWiG. [A20-74] Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - benefit assessment according to \u00a735a Social Code Book V. www.iqwig.de\/en\/projects\/a20-74.html [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0180","unstructured":"IQWiG. [A19-90] Larotrectinib (solid tumours) - benefit assessment according to \u00a735a Social Code Book V. www.iqwig.de\/en\/projects\/a19-90.html [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0185","unstructured":"Gemeinsamer Bundesausschuss. Arzneimittel-Richtlinie\/Anlage XII: Entrectinib (solide Tumore; Histologie-unabh\u00e4ngig). www.g-ba.de\/beschluesse\/4715\/ [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0190","unstructured":"Gemeinsamer Bundesausschuss. Arzneimittel-Richtlinie\/Anlage XII: Larotrectinib (solide Tumore, Histologie-unabh\u00e4ngig). www.g-ba.de\/beschluesse\/4242\/ [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0195","unstructured":"Zorginstituut Nederland. Ministerie van Volksgezondheid, Welzijn en Sport. Vervolgadvies over voorwaardelijke toelating larotrectinib (Vitrakvi\u00ae) \u2013 Advies. www.zorginstituutnederland.nl\/publicaties\/adviezen\/2021\/08\/16\/vervolgadvies-over-voorwaardelijke-toelating-larotrectinib-vitrakvi [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0200","unstructured":"Zorginstituut Nederland. Ministerie van Volksgezondheid, Welzijn en Sport. Vervolgadvies over voorwaardelijke toelating entrectinib (Rozlytrek\u00ae) \u2013 Advies. www.zorginstituutnederland.nl\/publicaties\/adviezen\/2021\/08\/16\/vervolgadvies-over-voorwaardelijke-toelating-entrectinib-rozlytrek [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0205","unstructured":"NICE. Overview | Larotrectinib for treating NTRK fusion-positive solid tumours | Guidance. www.nice.org.uk\/guidance\/ta630 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0210","unstructured":"NHS England. Cancer Drugs Fund. www.england.nhs.uk\/cancer\/cdf\/ [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0215","unstructured":"NICE. Overview | Entrectinib for treating NTRK fusion-positive solid tumours | Guidance. www.nice.org.uk\/guidance\/ta644 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0220","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.annonc.2020.08.2232","article-title":"Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network","volume":"31","author":"Demetri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO\u2013European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.drudis.2024.104031_b0230","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0240","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0245","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0255","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0260","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO. https:\/\/www.esmo.org\/content\/download\/347819\/6934778\/1\/ESMO-CPG-MNSCLC-15SEPT2020.pdf Published online 2020. [Accessed March 25, 2023]."},{"key":"10.1016\/j.drudis.2024.104031_b0265","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0270","unstructured":"European Society For Medical Oncology. ESMO-MCBS scorecards. www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-scorecards [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0275","unstructured":"European Society For Medical Oncology. ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). www.esmo.org\/policy\/esmo-scale-for-clinical-actionability-of-molecular-targets-escat [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0280","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104031_b0285","unstructured":"BeNeLuxA. Horizon Scanning. https:\/\/beneluxa.org\/horizonscanning [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0290","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nrd4129","article-title":"The risks of risk aversion in drug regulation","volume":"12","author":"Eichler","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104031_b0295","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jval.2022.05.006","article-title":"Differences in evidentiary requirements between European Medicines Agency and European Health Technology Assessment of oncology drugs\u2014can alignment be enhanced?","volume":"25","author":"Wolters","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2024.104031_b0300","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jval.2019.07.007","article-title":"Unmet medical need: an introduction to definitions and stakeholder perceptions","volume":"22","author":"Vreman","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2024.104031_b0305","series-title":"Transparency Committee doctrine - Principles of Medicinal Product Assessments and Appraisal for Reimbursement Purposes","author":"Gatulli","year":"2020"},{"key":"10.1016\/j.drudis.2024.104031_b0310","series-title":"Specialist Medicinal Products Assessment Procedure","author":"Ophuis","year":"2020"},{"key":"10.1016\/j.drudis.2024.104031_b0315","unstructured":"EUnetHTA 21. Methodological guideline on direct and indirect comparisons V1.0. www.eunethta.eu\/wp-content\/uploads\/2022\/08\/EUnetHTA-21-Deliverable-D4.3.2-Methodological-Guideline-on-Direct-and-indirect-comparisons-V1.0.pdf [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0320","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/ph16040614","article-title":"Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics","volume":"16","author":"Tateo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2024.104031_b0325","unstructured":"European Medicines Agency. Retsevmo \u2013 opinion on variation to marketing authorisation. www.ema.europa.eu\/en\/medicines\/human\/variation\/retsevmo [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0330","unstructured":"European Medicines Agency. Rozlytrek \u2013 opinion on variation to marketing authorisation. www.ema.europa.eu\/en\/medicines\/human\/variation\/rozlytrek [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0335","first-page":"e072309","article-title":"How to build bridges between regulation, health technology assessment and clinical guideline development: focus groups with European experts","volume":"13","author":"Hogervorst","year":"2023","journal-title":"Br Med J Open"},{"key":"10.1016\/j.drudis.2024.104031_b0340","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/bcp.13023","article-title":"How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice","volume":"82","author":"Tafuri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2024.104031_b0345","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jval.2017.11.003","article-title":"Building synergy between regulatory and HTA agencies beyond processes and procedures-can we effectively align the evidentiary requirements? A survey of stakeholder perceptions","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.drudis.2024.104031_b0350","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpt.1835","article-title":"Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe","volume":"108","author":"Vreman","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104031_b0355","series-title":"Pakketadvies entrectinib en larotrectinib (Rozlytrek\u00ae en Vitrakvi\u00ae) voor de behandeling van volwassen en kinderen met solide tumoren (kanker) met NTRK-genfusie","author":"Nederland","year":"2023"},{"key":"10.1016\/j.drudis.2024.104031_b0360","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40258-021-00654-4","article-title":"Developing a framework for the health technology assessment of histology-independent precision oncology therapies","volume":"19","author":"Gaultney","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.drudis.2024.104031_b0365","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jval.2023.01.011","article-title":"Challenges and solutions for the benefit assessment of tumor-agnostic therapies in Germany","volume":"26","author":"Schiller","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2024.104031_b0370","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jval.2023.07.004","article-title":"Toward best practices for economic evaluations of tumor-agnostic therapies: a review of current barriers and solutions","volume":"26","author":"Weymann","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2024.104031_b0375","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/cpt.1946","article-title":"Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine","volume":"109","author":"Seligson","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104031_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.893400","article-title":"A comparison of post-marketing measures imposed by regulatory agencies to confirm the tissue-agnostic approach","volume":"9","author":"Mulder","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2024.104031_b0385","unstructured":"NVMO. Over de adviezen. www.nvmo.org\/over-de-adviezen\/ [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0390","unstructured":"National Cancer Institute (NCI). Adjuvant nivolumab in resected lung cancers (ANVIL)-a randomized Phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02595944 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0395","unstructured":"National Cancer Institute (NCI). Randomized study of erlotinib vs observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193282 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0400","unstructured":"ECOG-ACRIN Cancer Research Group. A randomized phase III trial for surgically resected early stage non-small cell lung cancer: crizotinib versus observation for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02201992 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0405","unstructured":"Institut Curie. A randomized proof-of-concept phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01771458 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0410","unstructured":"M.D. Anderson Cancer Center. Randomized study evaluating molecular profiling and targeted agents in metastatic cancer: initiative for molecular profiling and advanced cancer therapy (IMPACT II). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02152254 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0415","unstructured":"Center for Drug Evaluation and Research. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors. Published online June 17, 2020 [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0420","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0425","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1016\/S1470-2045(21)00337-5","article-title":"Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment","volume":"22","author":"Lenglin\u00e9","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0430","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(21)00717-8","article-title":"Assessment of tumour-agnostic therapies in basket trials","volume":"23","author":"Collignon","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0435","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/S1470-2045(21)00714-2","article-title":"Assessment of tumour-agnostic therapies in basket trials","volume":"23","author":"Popat","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2024.104031_b0440","unstructured":"European Medicines Agency. Parallel joint scientific consultation with regulators and health technology assessment bodies. www.ema.europa.eu\/en\/human-regulatory\/research-development\/scientific-advice-protocol-assistance\/parallel-joint-scientific-consultation-regulators-health-technology-assessment-bodies [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0445","article-title":"How should we assess the clinical and cost effectiveness of histology independent cancer drugs?","volume":"368","author":"Cooper","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2024.104031_b0450","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jval.2014.04.006","article-title":"Improving the contribution of regulatory assessment reports to health technology assessments\u2014a collaboration between the European Medicines Agency and the European Network for Health Technology Assessment","volume":"17","author":"Berntgen","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2024.104031_b0455","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1017\/S026646232100057X","article-title":"Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements","volume":"37","author":"Eichler","year":"2021","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.drudis.2024.104031_b0460","unstructured":"European Commission. Regulation on Health Technology Assessment. https:\/\/health.ec.europa.eu\/health-technology-assessment\/regulation-health-technology-assessment_en [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0465","unstructured":"European Commission. Proposal for a Regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency. https:\/\/health.ec.europa.eu\/publications\/proposal-regulation-laying-down-union-procedures-authorisation-and-supervision-medicinal-products_en [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0470","unstructured":"European Medicines Agency. Academia. www.ema.europa.eu\/en\/partners-networks\/academia [Accessed May 12, 2024]."},{"key":"10.1016\/j.drudis.2024.104031_b0475","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1017\/S0266462323000090","article-title":"Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment","volume":"39","author":"Trowman","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.drudis.2024.104031_b0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2020.11.005","article-title":"Weekly updates of national living evidence-based guidelines: methods for the Australian living guidelines for care of people with COVID-19","volume":"131","author":"Tendal","year":"2021","journal-title":"J Clin Epidemiol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T19:33:32Z","timestamp":1720121612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624001569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":96,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1359644624001569"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104031","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104031"}}